Pharmaceutical compositions comprising a combination of rapamycin or its derivative and pimecrolimus for the treatment of inflammation-and ummunologically-mediated diseases
OwnerHenrietta Mooreinventor
Life of this patent
Estimating the term…
Abstract
The present invention relates to pharmaceutical compositions comprising in combination rapamycin or a rapamycin derivative and a compound of formula I, e.g. useful for the treatment of inflammatory and immunologically-mediated diseases, including autoimmune diseases.
Claims17
Pharmaceutical composition comprising in combination rapamycin or a rapamycin derivative and a compound of formula
- wherein either
- R1 is a group (a) of formula
- wherein
- R5 is chloro, bromo, iodo or azido,
- R6 is hydroxy or methoxy, and
- R4 is hydroxy and there is a single bond in 10,11 position;
- or absent, and there is a double bond in 10,11 position
- or
- R1 is a group (b) or (c) of formula
- wherein
- R6 is as defined above, and
- R4 is hydroxy and there is a single bond in 10,11 position,
- R2 is oxo and there is a single bond in 23,24 position;
- optionally protected hydroxy and there is a single or double bond in 23,24 position;
- or absent and there is a double bond in 23,24 position;
- R3 is methyl, ethyl, propyl or allyl.
- beside at least one pharmaceutically acceptable excipient.
Pharmaceutical kit of parts comprising in combination rapamycin or a rapamycin derivative and a compound of formula I beside instructions for simultaneous or sequential administration.
Use of a combination of rapamycin or a rapamycin derivative and a compound of formula I as a pharmaceutical.
Use of a combination of rapamycin or a rapamycin derivative and a compound of formula I for the manufacture of a medicament for the treatment of inflammatory bowel disease and diseases associated therewith.
Use of a combination of rapamycin or a rapamycin derivative and a compound of formula I for the manufacture of a medicament for the treatment of a disease selected from the group consisting of atopic dermatitis, contact dermatitis and further eczematous dermatoses, seborrhoeic dermatitis, contact hypersensitivity, Lichen planus, Pemphigus, bullous Pemphigoid, Epidermolysis bullosa, urticaria, angioedemas, vasculitides, erythemas, cutaneous eosinophilias and acne.
Use of a combination of rapamycin or a rapamycin derivative and a compound of formula
- wherein
- R1 is hydroxy or protected hydroxy,
- R2 is hydrogen, hydroxyl or protected hydroxyl,
- R3 is methyl, ethyl, propyl or allyl,
- n is an integer of 1 or 2, and
- the symbol of a line and dotted line is a single bond for the manufacture of a medicament for the treatment of a disease selected from the group consisting of atopic dermatitis, contact dermatitis and further eczematous dermatoses, seborrhoeic dermatitis, contact hypersensitivity, Lichen planus, Pemphigus, bullous Pemphigoid, Epidermolysis bullosa, urticaria, angioedemas, vasculitides, erythemas, cutaneous eosinophilias and acne.
Use of a combination of rapamycin or a rapamycin derivative and a compound of formula III for the manufacture of a medicament for the treatment of inflammatory bowel disease and diseases associated therewith.
Use of a compound of formula
- wherein
- R1 is methyl or (C3-6)alkynyl,
- R2 is H, —CH2—CH2—OH, 3-hydroxy-2-(hydroxymethyl)-2-methyl-propanoyl or tetrazolyl,
- X is =O, (H,H) or (H,OH),
- provided that R2 is other than H when X is =O and R1 is CH3,
- or a prodrug thereof when R2 is —CH2—CH2—OH for the manufacture of a medicament for the treatment of atopic dermatitis, contact dermatitis and further eczematous dermatoses, seborrhoeic dermatitis, contact hypersensitivity, Lichen planus, Pemphigus, bullous Pemphigoid, Epidermolysis bullosa, urticaria, angioedemas, vasculitides, erythemas, cutaneous eosinophilias and acne.
Dependencies are inferred from the claim text.